Radionuclide therapy using I-131-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

Introduction Anti-epidermal growth factor receptor (EGFR)-targeted nanoparticles can be used to deliver a therapeutic and imaging agent to EGFR-overexpressing tumor cells. I-131-labeled anti-EGFR nanoparticles derived from cetuximab were used as a tumor-targeting vehicle in radionuclide therapy

Evaluation of therapeutic effectiveness of I-131-antiEGFR-BSA-PCL in a mouse model of colorectal cancer

AIM: To investigate the biological effects of internal irradiation, and the therapeutic effectiveness was assessed of I-131-labeled anti-epidermal growth factor receptor (EGFR) liposomes, derived from cetuximab, when used as a tumor-targeting carrier in a colorectal cancer mouse model